Influence of repeated treatment with buspirone on central 5-hydroxytryptamine and dopamine synthesis

G. Tunnicliff, J. J. Brokaw, J. A. Hausz, G. K. Matheson, Gary White

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The anxiolytic agent buspirone was administered subcutaneously twice a day for 10 days to Sprague-Dawley rats, at a dose of 3 mg kg-1. Controls were given saline. On the eleventh day, the rats were given an injection of NSD-1015, an aromatic L-amino acid decarboxylase inhibitor, 30 min before decapitation. To another group of rats, only one injection of buspirone was given, followed 30 min later by NSD-1015. After a further 30 min the animals were decapitated. The brains were rapidly removed and the raphe nuclei, striatum, hippocampus and cerebellum were dissected out on to dry ice. With the use of HPLC, the four regions of the brain were assayed for 5-hydroxytryptophan and 3,4-dihydroxyphenylalanine, reflecting the synthesis of 5-HT and dopamine, respectively. In those rats which had received an acute dose of buspirone, the synthesis of 5-HT was substantially reduced in all four regions of the brain. However, in those rats which had received buspirone for 10 days, no such alterations in the synthesis of 5-HT were observed. The synthesis of dopamine was unchanged in any of the regions of the brain, after the acute dose of buspirone. After 10 days of treatment with buspirone, however, the synthesis of dopamine in the striatum was significantly reduced. These findings suggest that repeated treatment with buspirone reduces the synthesis of dopamine in the striatum but that the synthesis of 5-HT is unaffected.

Original languageEnglish
Pages (from-to)991-995
Number of pages5
JournalNeuropharmacology
Volume31
Issue number10
DOIs
StatePublished - 1992

Fingerprint

Buspirone
Dopamine
Serotonin
Brain
Therapeutics
Dry Ice
Aromatic-L-Amino-Acid Decarboxylases
Decapitation
5-Hydroxytryptophan
Dihydroxyphenylalanine
Injections
Raphe Nuclei
Anti-Anxiety Agents
Cerebellum
Sprague Dawley Rats
Hippocampus
High Pressure Liquid Chromatography

Keywords

  • 5-HT synthesis
  • 5-HT receptors
  • buspirone
  • dopamine synthesis
  • striatum

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Influence of repeated treatment with buspirone on central 5-hydroxytryptamine and dopamine synthesis. / Tunnicliff, G.; Brokaw, J. J.; Hausz, J. A.; Matheson, G. K.; White, Gary.

In: Neuropharmacology, Vol. 31, No. 10, 1992, p. 991-995.

Research output: Contribution to journalArticle

Tunnicliff, G. ; Brokaw, J. J. ; Hausz, J. A. ; Matheson, G. K. ; White, Gary. / Influence of repeated treatment with buspirone on central 5-hydroxytryptamine and dopamine synthesis. In: Neuropharmacology. 1992 ; Vol. 31, No. 10. pp. 991-995.
@article{d1fafaab3b794466ad019d885ecb655f,
title = "Influence of repeated treatment with buspirone on central 5-hydroxytryptamine and dopamine synthesis",
abstract = "The anxiolytic agent buspirone was administered subcutaneously twice a day for 10 days to Sprague-Dawley rats, at a dose of 3 mg kg-1. Controls were given saline. On the eleventh day, the rats were given an injection of NSD-1015, an aromatic L-amino acid decarboxylase inhibitor, 30 min before decapitation. To another group of rats, only one injection of buspirone was given, followed 30 min later by NSD-1015. After a further 30 min the animals were decapitated. The brains were rapidly removed and the raphe nuclei, striatum, hippocampus and cerebellum were dissected out on to dry ice. With the use of HPLC, the four regions of the brain were assayed for 5-hydroxytryptophan and 3,4-dihydroxyphenylalanine, reflecting the synthesis of 5-HT and dopamine, respectively. In those rats which had received an acute dose of buspirone, the synthesis of 5-HT was substantially reduced in all four regions of the brain. However, in those rats which had received buspirone for 10 days, no such alterations in the synthesis of 5-HT were observed. The synthesis of dopamine was unchanged in any of the regions of the brain, after the acute dose of buspirone. After 10 days of treatment with buspirone, however, the synthesis of dopamine in the striatum was significantly reduced. These findings suggest that repeated treatment with buspirone reduces the synthesis of dopamine in the striatum but that the synthesis of 5-HT is unaffected.",
keywords = "5-HT synthesis, 5-HT receptors, buspirone, dopamine synthesis, striatum",
author = "G. Tunnicliff and Brokaw, {J. J.} and Hausz, {J. A.} and Matheson, {G. K.} and Gary White",
year = "1992",
doi = "10.1016/0028-3908(92)90099-B",
language = "English",
volume = "31",
pages = "991--995",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Influence of repeated treatment with buspirone on central 5-hydroxytryptamine and dopamine synthesis

AU - Tunnicliff, G.

AU - Brokaw, J. J.

AU - Hausz, J. A.

AU - Matheson, G. K.

AU - White, Gary

PY - 1992

Y1 - 1992

N2 - The anxiolytic agent buspirone was administered subcutaneously twice a day for 10 days to Sprague-Dawley rats, at a dose of 3 mg kg-1. Controls were given saline. On the eleventh day, the rats were given an injection of NSD-1015, an aromatic L-amino acid decarboxylase inhibitor, 30 min before decapitation. To another group of rats, only one injection of buspirone was given, followed 30 min later by NSD-1015. After a further 30 min the animals were decapitated. The brains were rapidly removed and the raphe nuclei, striatum, hippocampus and cerebellum were dissected out on to dry ice. With the use of HPLC, the four regions of the brain were assayed for 5-hydroxytryptophan and 3,4-dihydroxyphenylalanine, reflecting the synthesis of 5-HT and dopamine, respectively. In those rats which had received an acute dose of buspirone, the synthesis of 5-HT was substantially reduced in all four regions of the brain. However, in those rats which had received buspirone for 10 days, no such alterations in the synthesis of 5-HT were observed. The synthesis of dopamine was unchanged in any of the regions of the brain, after the acute dose of buspirone. After 10 days of treatment with buspirone, however, the synthesis of dopamine in the striatum was significantly reduced. These findings suggest that repeated treatment with buspirone reduces the synthesis of dopamine in the striatum but that the synthesis of 5-HT is unaffected.

AB - The anxiolytic agent buspirone was administered subcutaneously twice a day for 10 days to Sprague-Dawley rats, at a dose of 3 mg kg-1. Controls were given saline. On the eleventh day, the rats were given an injection of NSD-1015, an aromatic L-amino acid decarboxylase inhibitor, 30 min before decapitation. To another group of rats, only one injection of buspirone was given, followed 30 min later by NSD-1015. After a further 30 min the animals were decapitated. The brains were rapidly removed and the raphe nuclei, striatum, hippocampus and cerebellum were dissected out on to dry ice. With the use of HPLC, the four regions of the brain were assayed for 5-hydroxytryptophan and 3,4-dihydroxyphenylalanine, reflecting the synthesis of 5-HT and dopamine, respectively. In those rats which had received an acute dose of buspirone, the synthesis of 5-HT was substantially reduced in all four regions of the brain. However, in those rats which had received buspirone for 10 days, no such alterations in the synthesis of 5-HT were observed. The synthesis of dopamine was unchanged in any of the regions of the brain, after the acute dose of buspirone. After 10 days of treatment with buspirone, however, the synthesis of dopamine in the striatum was significantly reduced. These findings suggest that repeated treatment with buspirone reduces the synthesis of dopamine in the striatum but that the synthesis of 5-HT is unaffected.

KW - 5-HT synthesis

KW - 5-HT receptors

KW - buspirone

KW - dopamine synthesis

KW - striatum

UR - http://www.scopus.com/inward/record.url?scp=0026439305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026439305&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(92)90099-B

DO - 10.1016/0028-3908(92)90099-B

M3 - Article

VL - 31

SP - 991

EP - 995

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 10

ER -